Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method

Hyunseok Peter Kang, Mitchell G. Scott, Bonnie N. Joe, Vamsi Narra, Jay Heiken, Curtis A. Parvin

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Gadolinium formulations, which are administered as contrast agents in magnetic resonance imaging examinations, interfere with colorimetric serum calcium determinations. Methods: We performed an in vitro study to determine the extent to which three gadolinium formulations -gadodiamide (Omniscan), gadopentetate dimeglumine (Magnevist), and gadoversetamide (OptiMARK) - affect measurements by two methods that use o-cresolphthalein (Dade Behring, Inc. and Roche Diagnostics) and one that uses arsenazo dye (Equal Diagnostics). We also compared values from the o-cresolphthalein methods for 116 samples from patients administered gadodiamide. Results: Magnevist did not affect any of the methods evaluated, whereas Omniscan and OptiMARK were identical in their effects. For the Dade method, the differences from the control sample were ≤4.0 and 7.0 mg/L at 0.25 and 0.5 mmol/L gadolinium, respectively. For the Roche method, the differences were 19, 9.0, and 5.0 mg/L at 0.5, 0.25, and 0.125 mmol/L gadolinium, respectively. Falsely increased calcium values were seen when samples were measured by the arsenazo-based method: differences were 6.0 and 3.0 mg/L at 1.0 and 0.5 mmol/L gadolinium. Using patient data collected at our institution, we were able to generate a model for predicting, from a patient's glomerular filtration rate and the time elapsed since administration, the impact of Omniscan on calcium measurements by the o-cresolphthalein method from Roche Diagnostics. Conclusions: The predictive model can be used to calculate, in patients who have received gadodiamide, the minimum length of time to wait before blood collection to avoid pseudohypocalcemia when the Roche o-cresolphthalein method is used.

Original languageEnglish (US)
Pages (from-to)741-746
Number of pages6
JournalClinical Chemistry
Volume50
Issue number4
DOIs
StatePublished - Apr 1 2004
Externally publishedYes

Fingerprint

gadodiamide
Gadolinium
Calcium
Plasmas
Gadolinium DTPA
Magnetic resonance
Contrast Media
cresolphthalein
Blood
Coloring Agents

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method. / Kang, Hyunseok Peter; Scott, Mitchell G.; Joe, Bonnie N.; Narra, Vamsi; Heiken, Jay; Parvin, Curtis A.

In: Clinical Chemistry, Vol. 50, No. 4, 01.04.2004, p. 741-746.

Research output: Contribution to journalArticle

Kang, Hyunseok Peter ; Scott, Mitchell G. ; Joe, Bonnie N. ; Narra, Vamsi ; Heiken, Jay ; Parvin, Curtis A. / Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method. In: Clinical Chemistry. 2004 ; Vol. 50, No. 4. pp. 741-746.
@article{4b118b8de07840bdaf15ece1930bf236,
title = "Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method",
abstract = "Background: Gadolinium formulations, which are administered as contrast agents in magnetic resonance imaging examinations, interfere with colorimetric serum calcium determinations. Methods: We performed an in vitro study to determine the extent to which three gadolinium formulations -gadodiamide (Omniscan), gadopentetate dimeglumine (Magnevist), and gadoversetamide (OptiMARK) - affect measurements by two methods that use o-cresolphthalein (Dade Behring, Inc. and Roche Diagnostics) and one that uses arsenazo dye (Equal Diagnostics). We also compared values from the o-cresolphthalein methods for 116 samples from patients administered gadodiamide. Results: Magnevist did not affect any of the methods evaluated, whereas Omniscan and OptiMARK were identical in their effects. For the Dade method, the differences from the control sample were ≤4.0 and 7.0 mg/L at 0.25 and 0.5 mmol/L gadolinium, respectively. For the Roche method, the differences were 19, 9.0, and 5.0 mg/L at 0.5, 0.25, and 0.125 mmol/L gadolinium, respectively. Falsely increased calcium values were seen when samples were measured by the arsenazo-based method: differences were 6.0 and 3.0 mg/L at 1.0 and 0.5 mmol/L gadolinium. Using patient data collected at our institution, we were able to generate a model for predicting, from a patient's glomerular filtration rate and the time elapsed since administration, the impact of Omniscan on calcium measurements by the o-cresolphthalein method from Roche Diagnostics. Conclusions: The predictive model can be used to calculate, in patients who have received gadodiamide, the minimum length of time to wait before blood collection to avoid pseudohypocalcemia when the Roche o-cresolphthalein method is used.",
author = "Kang, {Hyunseok Peter} and Scott, {Mitchell G.} and Joe, {Bonnie N.} and Vamsi Narra and Jay Heiken and Parvin, {Curtis A.}",
year = "2004",
month = "4",
day = "1",
doi = "10.1373/clinchem.2003.028886",
language = "English (US)",
volume = "50",
pages = "741--746",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "4",

}

TY - JOUR

T1 - Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method

AU - Kang, Hyunseok Peter

AU - Scott, Mitchell G.

AU - Joe, Bonnie N.

AU - Narra, Vamsi

AU - Heiken, Jay

AU - Parvin, Curtis A.

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Background: Gadolinium formulations, which are administered as contrast agents in magnetic resonance imaging examinations, interfere with colorimetric serum calcium determinations. Methods: We performed an in vitro study to determine the extent to which three gadolinium formulations -gadodiamide (Omniscan), gadopentetate dimeglumine (Magnevist), and gadoversetamide (OptiMARK) - affect measurements by two methods that use o-cresolphthalein (Dade Behring, Inc. and Roche Diagnostics) and one that uses arsenazo dye (Equal Diagnostics). We also compared values from the o-cresolphthalein methods for 116 samples from patients administered gadodiamide. Results: Magnevist did not affect any of the methods evaluated, whereas Omniscan and OptiMARK were identical in their effects. For the Dade method, the differences from the control sample were ≤4.0 and 7.0 mg/L at 0.25 and 0.5 mmol/L gadolinium, respectively. For the Roche method, the differences were 19, 9.0, and 5.0 mg/L at 0.5, 0.25, and 0.125 mmol/L gadolinium, respectively. Falsely increased calcium values were seen when samples were measured by the arsenazo-based method: differences were 6.0 and 3.0 mg/L at 1.0 and 0.5 mmol/L gadolinium. Using patient data collected at our institution, we were able to generate a model for predicting, from a patient's glomerular filtration rate and the time elapsed since administration, the impact of Omniscan on calcium measurements by the o-cresolphthalein method from Roche Diagnostics. Conclusions: The predictive model can be used to calculate, in patients who have received gadodiamide, the minimum length of time to wait before blood collection to avoid pseudohypocalcemia when the Roche o-cresolphthalein method is used.

AB - Background: Gadolinium formulations, which are administered as contrast agents in magnetic resonance imaging examinations, interfere with colorimetric serum calcium determinations. Methods: We performed an in vitro study to determine the extent to which three gadolinium formulations -gadodiamide (Omniscan), gadopentetate dimeglumine (Magnevist), and gadoversetamide (OptiMARK) - affect measurements by two methods that use o-cresolphthalein (Dade Behring, Inc. and Roche Diagnostics) and one that uses arsenazo dye (Equal Diagnostics). We also compared values from the o-cresolphthalein methods for 116 samples from patients administered gadodiamide. Results: Magnevist did not affect any of the methods evaluated, whereas Omniscan and OptiMARK were identical in their effects. For the Dade method, the differences from the control sample were ≤4.0 and 7.0 mg/L at 0.25 and 0.5 mmol/L gadolinium, respectively. For the Roche method, the differences were 19, 9.0, and 5.0 mg/L at 0.5, 0.25, and 0.125 mmol/L gadolinium, respectively. Falsely increased calcium values were seen when samples were measured by the arsenazo-based method: differences were 6.0 and 3.0 mg/L at 1.0 and 0.5 mmol/L gadolinium. Using patient data collected at our institution, we were able to generate a model for predicting, from a patient's glomerular filtration rate and the time elapsed since administration, the impact of Omniscan on calcium measurements by the o-cresolphthalein method from Roche Diagnostics. Conclusions: The predictive model can be used to calculate, in patients who have received gadodiamide, the minimum length of time to wait before blood collection to avoid pseudohypocalcemia when the Roche o-cresolphthalein method is used.

UR - http://www.scopus.com/inward/record.url?scp=1842451550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842451550&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2003.028886

DO - 10.1373/clinchem.2003.028886

M3 - Article

C2 - 14962999

AN - SCOPUS:1842451550

VL - 50

SP - 741

EP - 746

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 4

ER -